About the Prize
The Longitude Prize on ALS aims to:
- Deliver and validate new, high-potential therapeutic drug targets through the use of cutting-edge AI.
- Curate the largest datasets in ALS and provide access to these data to all prize participants, with compute power and data support.
- Build international, multi-disciplinary collaborations between AI-focused biotech and ALS researchers.
- Raise awareness of ALS globally and campaign for better use of patient data.
- Build a deeper understanding of ALS biology to the benefit of the scientific and patient community.
- Raise investor interest in the therapeutic potential of discoveries from the Prize.
ALS is a highly complex disease for which there are no effective treatments. The great promise is that AI can now handle this complexity. That’s why we predict that ALS shall be the first disease to become treatable due to AI. This prize is a rallying call for AI and ALS experts everywhere.